Deborah T. Gold

Deborah T. Gold

Professor in Psychiatry and Behavioral Sciences

External address: 
1507 Busse Bldg, Durham, NC 27710
Internal office address: 
Box 3003 Med Ctr, Durham, NC 27710
Phone: 
(919) 660-7530

Overview

My research has centered on the psychosocial consequences of chronic illness for older adults. Although I have studied breast cancer, syncope, head and neck cancer, Parkinson's disease and Paget's disease of bone, my primary interest and focus has been on osteoporosis and its psychological and social impact on those who suffer from it.

In particular, my current research focuses on compliance and persistence with osteoporosis medications. One current study focuses on the impact of race/ethnicity on medication decision making. We are trying to determine the relative weight of cost, convenience, dosing interval, efficacy, and safety in making medication decisions and taking medication on a regular basis as prescribed by a health care provider. I am also on the Steering Committees of two major observational studies with different osteoporosis medications.

Finally, I have worked with voluntary health organizations to translate our research findings into positive real-world outcomes for people with chronic illness. I serve on the Board of Trustees of the National Osteoporosis Foundation and am Chair of its Education Committee. I have also chaired the International Symposium on Osteoporosis (ISO) for the last 8 years.

Education & Training

  • Ph.D., Northwestern University 1986

Selected Grants

Behavior and Physiology in Aging awarded by National Institutes of Health (Director). 2015 to 2020

Behavioral and Physiology in Aging awarded by National Institutes of Health (Director). 2015 to 2020

Behavior And Physiology In Aging awarded by National Institutes of Health (Project Coordinator). 1999 to 2015

APOE, Quality of Life and Medical Costs in Late Life awarded by National Institutes of Health (Co Investigator). 2000 to 2004

Phase Ten Year Followup awarded by National Institutes of Health (Co Investigator). 1997 to 2000

Phse Ten Year Follow-Up awarded by National Institutes of Health (Co-Principal Investigator). 1995 to 1999

Phse Ten-Year Follow Up awarded by National Institutes of Health (Co-Principal Investigator). 1995 to 1999

Claude D Pepper Older Americans Independence Center awarded by National Institutes of Health (Co-Principal Investigator). 1992 to 1999

Alzheimer'S Disease Research Center awarded by National Institutes of Health (Co-Principal Investigator). 1985 to 1999

Osteoporosis And Disability In Life Care Community Women awarded by National Institutes of Health (Principal Investigator). 1992 to 1997

Pages

Silverman, S. L., and D. T. Gold. “Adherence to osteoporosis therapies.” Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2018, pp. 593–96. Scopus, doi:10.1002/9781119266594.ch78. Full Text

Gold, D. T. “Compliance and Persistence with Osteoporosis Medications.” Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition, 2013, pp. 448–54. Scopus, doi:10.1002/9781118453926.ch54. Full Text

Silverman, Stuart, and Deborah T. Gold. “Medication Decision-making in Osteoporosis: Can We Explain Why Patients Do Not Take Their Osteoporosis Medications?.” Curr Osteoporos Rep, vol. 16, no. 6, Dec. 2018, pp. 772–74. Pubmed, doi:10.1007/s11914-018-0494-0. Full Text

Silverman, Stuart L., et al. “Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study..” Arch Osteoporos, vol. 13, no. 1, Aug. 2018. Pubmed, doi:10.1007/s11657-018-0491-z. Full Text

Kerr, C., et al. “The importance of physical function to people with osteoporosis..” Osteoporos Int, vol. 28, no. 5, May 2017, pp. 1597–607. Pubmed, doi:10.1007/s00198-017-3911-9. Full Text

Diez-Perez, A., et al. “International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates..” Osteoporos Int, vol. 28, no. 3, Mar. 2017, pp. 767–74. Pubmed, doi:10.1007/s00198-017-3906-6. Full Text

Eastell, Richard, et al. “Postmenopausal osteoporosis..” Nat Rev Dis Primers, vol. 2, Sept. 2016. Pubmed, doi:10.1038/nrdp.2016.69. Full Text

Modi, Ankita, et al. “Association Between Gastrointestinal Events and Health Care Resource Utilization Among Patients with Osteoporosis: Analysis of a U.S. Managed Care Population..” J Manag Care Spec Pharm, vol. 21, no. 9, Sept. 2015, pp. 811–21. Pubmed, doi:10.18553/jmcp.2015.21.9.811. Full Text

Silverman, S. L., et al. “Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study..” Osteoporos Int, vol. 26, no. 1, Jan. 2015, pp. 361–72. Pubmed, doi:10.1007/s00198-014-2871-6. Full Text

Gold, Deborah T., et al. “A Patient Survey Study of Zoledronic Acid Utilization and Factors Associated with Persistence..” Arthritis & Rheumatology, vol. 66, WILEY-BLACKWELL, Oct. 2014, pp. S509–S509.

Pages

Silverman, S. L., et al. “Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.” Osteoporosis International, Springer-Verlag London Ltd, 2014. Scopus, doi:10.1007/s00198-014-2871-6. Full Text

Gold, Deborah T., et al. “RACE/ETHNICITYAND SES INFLUENCE OUTCOMES OF OSTEOPOROSIS EDUCATIONAL INTERVENTIONS.” Osteoporosis International, vol. 25, SPRINGER LONDON LTD, 2014, pp. S517–S517.

Lunsford, Julia, et al. “Reports of Depression in Older Women with Osteoporosis.” The American Journal of Geriatric Psychiatry, vol. 22, no. 3, Elsevier BV, 2014, pp. S69–70. Crossref, doi:10.1016/j.jagp.2013.12.075. Full Text

Gold, Deborah T., et al. “THE IMPACT OF HEALTH BELIEFS ON OSTEOPOROSIS TREATMENT.” Osteoporosis International, vol. 24, SPRINGER LONDON LTD, 2013, pp. S437–38.

Silverman, Stuart, et al. “INTERNATIONAL COST AND UTILITIES RELATED TO OSTEOPOROSIS FRACTURE STUDY IN USA (ICUROS-US); STUDY DESIGN AND METHODS.” Osteoporosis International, vol. 20, SPRINGER LONDON LTD, 2009, pp. S219–S219.

Abelson, Abby, et al. “REAL-WORLD EFFECTIVENESS OF BISPHOSPHONATES FOR THE REDUCTION OF CLINICAL FRACTURES.” Osteoporosis International, vol. 20, SPRINGER LONDON LTD, 2009, pp. S218–19.

Gold, Deborah T., et al. “PATIENT PREFERENCE AND SATISFACTION WITH A 6-MONTH INJECTION VERSUS A WEEKLY PILL FOR TREATMENT OF POSTMENOPAUSAL BONE LOSS.” Osteoporosis International, vol. 20, SPRINGER LONDON LTD, 2009, pp. S201–02.

Gold, Deborah T., et al. “Monthly ibandronate did not improve patient persistence vs weekly risedronate: 1 year data.” Osteoporosis International, vol. 18, SPRINGER LONDON LTD, 2007, pp. S223–24.

Gold, Deborah T. “Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses..” Journal of Managed Care Pharmacy : Jmcp, vol. 12, no. 6 Suppl A, 2006, pp. S20–25. Epmc, doi:10.18553/jmcp.2006.12.s6-a.s20. Full Text